Brokerages expect AxoGen, Inc (NASDAQ:AXGN) to post sales of $26.73 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for AxoGen’s earnings. The lowest sales estimate is $26.50 million and the highest is $26.90 million. AxoGen posted sales of $20.59 million in the same quarter last year, which suggests a positive year over year growth rate of 29.8%. The firm is expected to issue its next quarterly earnings results on Wednesday, August 7th.
On average, analysts expect that AxoGen will report full year sales of $111.83 million for the current fiscal year, with estimates ranging from $111.00 million to $112.40 million. For the next year, analysts anticipate that the company will report sales of $147.70 million, with estimates ranging from $145.00 million to $150.30 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow AxoGen.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, May 8th. The medical equipment provider reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). AxoGen had a negative net margin of 29.19% and a negative return on equity of 15.58%. The business had revenue of $23.30 million for the quarter, compared to analyst estimates of $22.33 million. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. The business’s revenue was up 34.7% on a year-over-year basis.
Several equities analysts recently issued reports on AXGN shares. BTIG Research decreased their target price on shares of Verastem to $8.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Canaccord Genuity boosted their target price on shares of Cogeco Communications from C$97.00 to C$104.00 and gave the company a “buy” rating in a research note on Friday. BidaskClub cut shares of Virtu Financial from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 target price on shares of Spero Therapeutics in a research note on Thursday, May 9th. Finally, ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. AxoGen currently has a consensus rating of “Buy” and an average price target of $36.50.
NASDAQ AXGN traded up $0.27 on Friday, hitting $20.46. 621,862 shares of the company’s stock traded hands, compared to its average volume of 333,329. The company has a quick ratio of 8.03, a current ratio of 8.83 and a debt-to-equity ratio of 0.02. AxoGen has a 1-year low of $14.13 and a 1-year high of $56.85. The stock’s 50-day moving average price is $20.33. The firm has a market cap of $796.71 million, a price-to-earnings ratio of -37.89 and a beta of 0.25.
In related news, Director Amy Mcbride Wendell acquired 5,000 shares of AxoGen stock in a transaction on Thursday, June 13th. The stock was bought at an average cost of $20.25 per share, for a total transaction of $101,250.00. Following the completion of the transaction, the director now owns 23,333 shares of the company’s stock, valued at approximately $472,493.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP David K. Hansen sold 20,000 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $22.63, for a total transaction of $452,600.00. Following the transaction, the vice president now owns 25,588 shares of the company’s stock, valued at $579,056.44. The disclosure for this sale can be found here. Insiders own 6.77% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Legal & General Group Plc raised its position in AxoGen by 5.8% during the fourth quarter. Legal & General Group Plc now owns 12,826 shares of the medical equipment provider’s stock worth $262,000 after acquiring an additional 702 shares during the period. Quantamental Technologies LLC raised its position in AxoGen by 108.3% during the first quarter. Quantamental Technologies LLC now owns 1,431 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 744 shares during the period. Cutler Group LP raised its position in AxoGen by 120.0% during the first quarter. Cutler Group LP now owns 2,200 shares of the medical equipment provider’s stock worth $46,000 after acquiring an additional 1,200 shares during the period. Citigroup Inc. raised its position in AxoGen by 17.4% during the fourth quarter. Citigroup Inc. now owns 9,905 shares of the medical equipment provider’s stock worth $202,000 after acquiring an additional 1,467 shares during the period. Finally, Lord Abbett & CO. LLC raised its position in AxoGen by 2.5% during the fourth quarter. Lord Abbett & CO. LLC now owns 106,905 shares of the medical equipment provider’s stock worth $2,184,000 after acquiring an additional 2,608 shares during the period. Institutional investors own 87.23% of the company’s stock.
AxoGen Company Profile
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Recommended Story: Earnings Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.